SKIN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SKIN is not a good buy right now for a beginner investor focused on the long term. The stock is in a bearish technical setup, recent fundamentals show declining sales, analysts are cautious with Hold ratings and lower price targets, and there is no strong proprietary trading signal to support an immediate entry. Given the user's impatience and desire to invest now, the better direct answer is to avoid buying SKIN at the current price.
Current price is 0.65875, down 3.97% in regular trading and 2.85% pre-market. The trend is weak: MACD histogram is negative, RSI_6 at 33.3 is near oversold but not a clear reversal signal, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price is below the pivot at 0.752 and closer to support at 0.598 than resistance at 0.907, which confirms a weak near-term trend. The stock trend model also suggests only modest short-term upside with weak near-term performance expectations.
["Q1 2026 adjusted EBITDA rose 17% year over year to $8.5 million.", "The company maintained full-year adjusted EBITDA guidance of $35 million to $45 million.", "Hedge funds are buying, with a very large reported increase in buying activity over the last quarter.", "Analysts noted FY26 EBITDA guidance may imply roughly 20% upside versus Street estimates."]
["Q1 2026 net sales fell 6.7% year over year to $64.9 million.", "Device placements came in below expectations and management expects continued softness in Q2.", "Macroeconomic pressure and competition are weighing on ordering and machine placements.", "Analysts cut price targets recently, signaling reduced confidence in near-term upside.", "No AI Stock Picker or SwingMax buy signal is present today.", "No recent congress trading data and no notable insider buying signal."]
Latest quarter: Q1 2026. Revenue declined 6.7% year over year to $64.9 million, showing that top-line growth remains under pressure. On the positive side, adjusted EBITDA increased 17% to $8.5 million, indicating some operating leverage or cost control. Management lowered the revenue outlook to $280 million-$295 million for the year, while keeping adjusted EBITDA guidance at $35 million-$45 million. That suggests margin resilience, but not strong growth momentum.
Recent analyst trend is negative-to-neutral. Canaccord cut its target to $1 from $1.50 and kept a Hold rating, and TD Cowen cut its target to $1.50 from $1.65 while also staying Hold. The Street view is mixed but cautious: pros include better-than-expected EBITDA potential and improving consumable sales, while cons include softer machine placements, macro pressure, and revenue weakness. Overall, Wall Street is not signaling a strong buy.
